title: [Effects of recombinant human interleukin 11 on hematological malignancy after allogeneic hematopoietic cell transplantation].
abstract: OBJECTIVE
  To investigate the effects of recombinant human interleukin 11 (rhIL-11) on hematological malignancy after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  
  
  METHODS
  A total of 48 patients with hematological malignancy from January 2006 to June 2010 were alternately enrolled into a prospective randomized study. And they were assigned into the control and rhIL-11 injection groups. Later the investigators compared two groups with regards to hematopoietic reconstitution, graft versus host disease (GVHD) classification, clinical recurrence rate and disease-free survival.
  
  
  RESULTS
  With the therapy of rhIL-11, the absolute neutrophil counts recovering to 0.5 × 10(9)/L and platelet recovering to 20 × 10(9)/L were (15.1 ± 1.6) and (18.2 ± 3.3) days respectively. And they were significantly lower than those in control group [(16.1 ± 1.6) vs (22.4 ± 5.5) days, P = 0.032, 0.003]. The incidence of acute GVHD was surprisingly low in the study group (26.1% vs 50.0%, P = 0.048). There was no significant difference in chronic GVHD (36.8% vs 38.9%, P = 0.899) or relapse rate (5.1% vs 7.7%, P = 0.662) between two groups during a median follow-up period of 11.7 months. A trend of improved 3-year-disease-free survival was observed in the study group (65.4% vs 50.9%, P = 0.637).
  
  
  CONCLUSIONS
  The application of rhIL-11 after allo-HSCT may accelerate both neutrophil and platelet engraftment and lower the occurrence of acute GVHD.
authors.affiliation: Department of Hematology, Nanfang Hospital, Nanfang Medical University, Guangzhou 510515, China.
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Xu
authors.forename: Xiao-Min
authors.initials: XM
authors.lastname: Niu
authors.forename: Zi-Wen
authors.initials: ZW
authors.lastname: Guo
authors.forename: Hui-Qing
authors.initials: HQ
authors.lastname: He
authors.forename: Da-Fa
authors.initials: DF
authors.lastname: Qiu
authors.forename: Can
authors.initials: C
authors.lastname: Liu
authors.forename: Shu-Hua
authors.initials: SH
authors.lastname: Lin
authors.forename: Kui
authors.initials: K
authors.lastname: Song
authors.forename: Zhi-Juan
authors.initials: ZJ
authors.lastname: Ren
authors.forename: Wei-Chao
authors.initials: WC
authors.lastname: Li
authors.forename: Gui-Nian
authors.initials: GN
authors.lastname: Huang
authors.forename: Qi-Fa
authors.initials: QF
authors.lastname: Liu
mesh_terms: D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control*; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017370:Interleukin-11 / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D015996:Survival Rate; D014184:Transplantation, Homologous
chemical_list: D017370:Interleukin-11; D011994:Recombinant Proteins